Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

E. P. Bouras, Michael Camilleri, D. D. Burton, G. Thomforde, S. McKinzie, A. R. Zinsmeister

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

Background & Aims: Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine4-receptor agonist with gastrointestinal and colonic prokinetic activities. We evaluated the effects of PRU on gastrointestinal and colonic transit in patients with constipation. Methods: Gastrointestinal and colonic transit were measured over 48 hours in 40 patients who fulfilled modified Rome I criteria for functional constipation. Patients had no evidence of a rectal evacuation disorder. Subjects were randomized to receive a daily dose of 2 or 4 mg PRU or placebo in a double-blind, parallel-group design. Each treatment lasted 7 days. The transit test was performed over the last 48 hours of the study. Effects on gastric emptying, small bowel transit, and colonic transit were analyzed using Kruskal-Wallis and Wilcoxon rank sum tests. Results: Of 61 patients screened, 40 were eligible and randomized. Two patients withdrew because of adverse events. PRU accelerated overall gastric emptying and small bowel transit. PRU tended to accelerate overall colonic transit with significantly faster overall colonic transit and ascending colon emptying with the 4-mg dose. Conclusions: PRU accelerates transit through the stomach, small bowel, and colon in patients with constipation unassociated with a rectal evacuation disorder.

Original languageEnglish (US)
Pages (from-to)354-360
Number of pages7
JournalGastroenterology
Volume120
Issue number2
StatePublished - 2001

Fingerprint

prucalopride
Rectal Diseases
Gastrointestinal Transit
Constipation
Gastric Emptying
Nonparametric Statistics
Ascending Colon
Stomach
Colon
Placebos

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bouras, E. P., Camilleri, M., Burton, D. D., Thomforde, G., McKinzie, S., & Zinsmeister, A. R. (2001). Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology, 120(2), 354-360.

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. / Bouras, E. P.; Camilleri, Michael; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R.

In: Gastroenterology, Vol. 120, No. 2, 2001, p. 354-360.

Research output: Contribution to journalArticle

Bouras, EP, Camilleri, M, Burton, DD, Thomforde, G, McKinzie, S & Zinsmeister, AR 2001, 'Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder', Gastroenterology, vol. 120, no. 2, pp. 354-360.
Bouras, E. P. ; Camilleri, Michael ; Burton, D. D. ; Thomforde, G. ; McKinzie, S. ; Zinsmeister, A. R. / Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. In: Gastroenterology. 2001 ; Vol. 120, No. 2. pp. 354-360.
@article{975efb6d55da42b4bcb24a576de26ce0,
title = "Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder",
abstract = "Background & Aims: Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine4-receptor agonist with gastrointestinal and colonic prokinetic activities. We evaluated the effects of PRU on gastrointestinal and colonic transit in patients with constipation. Methods: Gastrointestinal and colonic transit were measured over 48 hours in 40 patients who fulfilled modified Rome I criteria for functional constipation. Patients had no evidence of a rectal evacuation disorder. Subjects were randomized to receive a daily dose of 2 or 4 mg PRU or placebo in a double-blind, parallel-group design. Each treatment lasted 7 days. The transit test was performed over the last 48 hours of the study. Effects on gastric emptying, small bowel transit, and colonic transit were analyzed using Kruskal-Wallis and Wilcoxon rank sum tests. Results: Of 61 patients screened, 40 were eligible and randomized. Two patients withdrew because of adverse events. PRU accelerated overall gastric emptying and small bowel transit. PRU tended to accelerate overall colonic transit with significantly faster overall colonic transit and ascending colon emptying with the 4-mg dose. Conclusions: PRU accelerates transit through the stomach, small bowel, and colon in patients with constipation unassociated with a rectal evacuation disorder.",
author = "Bouras, {E. P.} and Michael Camilleri and Burton, {D. D.} and G. Thomforde and S. McKinzie and Zinsmeister, {A. R.}",
year = "2001",
language = "English (US)",
volume = "120",
pages = "354--360",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

AU - Bouras, E. P.

AU - Camilleri, Michael

AU - Burton, D. D.

AU - Thomforde, G.

AU - McKinzie, S.

AU - Zinsmeister, A. R.

PY - 2001

Y1 - 2001

N2 - Background & Aims: Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine4-receptor agonist with gastrointestinal and colonic prokinetic activities. We evaluated the effects of PRU on gastrointestinal and colonic transit in patients with constipation. Methods: Gastrointestinal and colonic transit were measured over 48 hours in 40 patients who fulfilled modified Rome I criteria for functional constipation. Patients had no evidence of a rectal evacuation disorder. Subjects were randomized to receive a daily dose of 2 or 4 mg PRU or placebo in a double-blind, parallel-group design. Each treatment lasted 7 days. The transit test was performed over the last 48 hours of the study. Effects on gastric emptying, small bowel transit, and colonic transit were analyzed using Kruskal-Wallis and Wilcoxon rank sum tests. Results: Of 61 patients screened, 40 were eligible and randomized. Two patients withdrew because of adverse events. PRU accelerated overall gastric emptying and small bowel transit. PRU tended to accelerate overall colonic transit with significantly faster overall colonic transit and ascending colon emptying with the 4-mg dose. Conclusions: PRU accelerates transit through the stomach, small bowel, and colon in patients with constipation unassociated with a rectal evacuation disorder.

AB - Background & Aims: Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine4-receptor agonist with gastrointestinal and colonic prokinetic activities. We evaluated the effects of PRU on gastrointestinal and colonic transit in patients with constipation. Methods: Gastrointestinal and colonic transit were measured over 48 hours in 40 patients who fulfilled modified Rome I criteria for functional constipation. Patients had no evidence of a rectal evacuation disorder. Subjects were randomized to receive a daily dose of 2 or 4 mg PRU or placebo in a double-blind, parallel-group design. Each treatment lasted 7 days. The transit test was performed over the last 48 hours of the study. Effects on gastric emptying, small bowel transit, and colonic transit were analyzed using Kruskal-Wallis and Wilcoxon rank sum tests. Results: Of 61 patients screened, 40 were eligible and randomized. Two patients withdrew because of adverse events. PRU accelerated overall gastric emptying and small bowel transit. PRU tended to accelerate overall colonic transit with significantly faster overall colonic transit and ascending colon emptying with the 4-mg dose. Conclusions: PRU accelerates transit through the stomach, small bowel, and colon in patients with constipation unassociated with a rectal evacuation disorder.

UR - http://www.scopus.com/inward/record.url?scp=0035121508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035121508&partnerID=8YFLogxK

M3 - Article

C2 - 11159875

AN - SCOPUS:0035121508

VL - 120

SP - 354

EP - 360

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -